Forma Therapeutics, Inc.

FORMA Therapeutics is integrating transformative biology and chemistry to unlock the best targets and pathways that genomics medicine has revealed. FORMA leverages its innovative drug discovery platform to address challenging targets and develop a robust internal pipeline of targeted breakthrough oncology drugs. FORMA is a global company headquartered in Cambridge, MA with additional research operations in Connecticut, Singapore and Beijing.

In The News

ZoBio and Domainex Join Forces to Deliver Crucial Drug Target Information to support FORMA Therapeutics’ Drug Discovery Programs

The goal of the collaboration is to use ZoBio’s expertise in protein nuclear magnetic resonance (NMR) to elucidate the molecular basis for compound-target interaction, to complement ongoing X-ray crystallography approaches.

Forma Therapeutics and Moffitt Cancer Center Establish Multiyear Epigenetics Alliance

FORMA Therapeutics and Moffitt Cancer Center announced today a bold, collaborative research initiative and exclusive license option agreement focused on histone deacetylases (HDACs) and epigenetics. Source: PipelineReview.com

FORMA Therapeutics Achieves First Major Objective to Advance Innovative Protein Homeostasis Drugs with Celgene Corporation
Current Investors/Backers

Forma Therapeutics, Inc. is backed by pharmaceutical giant Novartis and its BioVenture fund.

For more information on Forma Therapeutics, Inc., please visit their web site at www.formatherapeutics.com.

ATEL VENTURE PORTFOLIO NEWS